Laboratory of Nanoradiopharmaceuticals

Rio de Janeiro, Brazil

Laboratory of Nanoradiopharmaceuticals

Rio de Janeiro, Brazil

Time filter

Source Type

Ligiero T.B.,Laboratory of Nanoradiopharmaceuticals | De Souza Albernaz M.,Federal University of Rio de Janeiro | De Carvalho S.M.,Laboratory of Nanoradiopharmaceuticals | De Oliveira S.M.V.,Radiation Protection Institute | Santos-Oliveira R.,Laboratory of Nanoradiopharmaceuticals
Current Radiopharmaceuticals | Year: 2013

In this study was carried on a systematic review of the data was carried out in the topic of monoclonal antibodies in the last 40 years. All the data collected and summarized revealed that this new class of medicine may bring great advance in the field of radiopharmacy, oncology and imaging. © 2013 Bentham Science Publishers.


Pinto S.R.,Zona Oeste Estadual University | Sarcinelle M.A.,Laboratory of Nanoradiopharmaceuticals | de Souza Albernaz M.,Laboratory of Nanoradiopharmaceuticals | da Silva F.M.R.,Laboratory of Nanoradiopharmaceuticals | And 5 more authors.
Nuclear Medicine and Biology | Year: 2014

The use of in vivo assay to determine the biodistribution and subsequent inter-comparison with human parameters has been used since the dawn of science. The use of this type of test admits the metabolic equity among animals for inter-comparison. Thus, the use of Wistar rats in particular is quite frequent. Regarding routes of administration, there are three ways to test priority: jugular vein, intraocular (eye plexus) and caudal; there is a consensus that these three pathways behave in the same way, or at least very similar. Biodistribution studies of drugs, especially radiopharmaceuticals, have been using randomly any of these pathways believed to be effective in their likeness without worrying about your real analytic equity. In this study, we performed in vivo assay in 8 Wistar rats using 99mTc -labeled Herceptin to review the route of administration on the biodistribution result. Thus, four mice were injected via the intraocular (eye plexus), and four were injected via tail (caudal plexus). The results were quite disparate and call the attention of the scientific community to reassess the protocols for animal experiments, in order to have uniformity and fairness between the data and may represent a test for human inter-comparison of more reliable and trustworthy way. © 2014 Elsevier Inc.


PubMed | Laboratory of Nanoradiopharmaceuticals and Zona Oeste Estadual University
Type: Comparative Study | Journal: Nuclear medicine and biology | Year: 2014

The use of in vivo assay to determine the biodistribution and subsequent inter-comparison with human parameters has been used since the dawn of science. The use of this type of test admits the metabolic equity among animals for inter-comparison. Thus, the use of Wistar rats in particular is quite frequent. Regarding routes of administration, there are three ways to test priority: jugular vein, intraocular (eye plexus) and caudal; there is a consensus that these three pathways behave in the same way, or at least very similar. Biodistribution studies of drugs, especially radiopharmaceuticals, have been using randomly any of these pathways believed to be effective in their likeness without worrying about your real analytic equity. In this study, we performed in vivo assay in 8 Wistar rats using 99mTc -labeled Herceptin to review the route of administration on the biodistribution result. Thus, four mice were injected via the intraocular (eye plexus), and four were injected via tail (caudal plexus). The results were quite disparate and call the attention of the scientific community to reassess the protocols for animal experiments, in order to have uniformity and fairness between the data and may represent a test for human inter-comparison of more reliable and trustworthy way.


De Carvalho Patricio B.F.,Federal University of Rio de Janeiro | De Carvalho Patricio B.F.,Laboratory of Nanoradiopharmaceuticals | De Souza Albernaz M.,Laboratory of Nanoradiopharmaceuticals | Sarcinelli M.A.,Laboratory of Nanoradiopharmaceuticals | And 3 more authors.
Journal of Biomedical Nanotechnology | Year: 2014

Bone metastasis is responsible for up to 99% of bone tumors. As no cure has yet to be discovered, available treatments simply strive to improve quality of life. One of such treatments is the use of EDTMP (ethylenediamine- tetramethylenephosphonic acid) labeled with Samarium-153, which has been shown to improve survival in 70-80% of patients treated. A major disadvantage of this radiopharmaceutical is its superficial delivery, resulting in the need for multiple doses. The current work describes novel polymeric nanoparticles of EDTMP and evaluation of their biodistribution in vivo. Nanoparticles were prepared using a double emulsion-solvent evaporation method and characterized by AFM (atomic force microscopy). Nanoparticles (200-500 nm) were then labeled with Technetium-99m for biodistribution analysis in healthy Wistar rats. Polymeric nanoparticles of EDTMP were observed to accumulate at bone tissue for long periods of time (150 min), resulting in prolonged release of EDTMP at the target site. This finding suggests that this novel pharmaceutical formulation of EDTMP provides better targeted delivery than free EDTMP and may be a more optimal treatment for management of bone metastasis pain. Copyright © 2014 American Scientific Publishers All rights reserved.


Da Silva F.M.R.,Laboratory of Nanoradiopharmaceuticals | Junior J.C.D.A.,Laboratory of Nanoradiopharmaceuticals | Oliveira E.E.D.M.,Brazilian Nuclear Engineering Institute (IEN) | Albernaz M.D.S.,University Hospital Clementino Fraga Filho | And 2 more authors.
Anti-Cancer Agents in Medicinal Chemistry | Year: 2016

The use of nanobiomaterials is increasing each day, especially for cancer diagnosis and therapy. Among the immense variety of nanomaterials developed and studied, the nanohydroxyapatite is one of the most studied. In this study, we developed and tested nanohydroxyapatite doped with Ho-166 for bone cancer. The results showed that the nanohydroxyapatite doped with Ho-166 has affinity for the bone, as also, the pre-clinical studies support the use as a nano-radiopharmaceuticals for bone cancer treatment and diagnosis. © 2016 Bentham Science Publishers.


Machado D.E.,Centro Universitario Estadual da Zona Oeste | Perini J.A.,Centro Universitario Estadual da Zona Oeste | Orlando M.M.C.,University Hospital Pedro Ernesto | Santos-Oliveira R.,Laboratory of Nanoradiopharmaceuticals
BioMed Research International | Year: 2015

The off-label use of bevacizumab labeled with 99mTc as a new radiopharmaceutical for imaging of endometriosis is a promising noninvasive, new clinical procedure. The bevacizumab in monoclonal antibodies targeted at vascular endothelial growth factor (VEGF) is superexpressed in cases of endometriosis. In this study we evaluate the imaging of endometriosis lesion in rats (induced to endometriosis) using bevacizumab-99mTc. The results showed that bevacizumab-99mTc imaged the lesion and support his use for Nuclear Medicine applied to gynecology. Also the results appointed that this radiopharmaceutical has a hepatobiliary excretion. It is important to notice that the dose used was almost 0,01% of the usual dose for the bevacizumab. Copyright © 2015 Daniel Escorsim Machado et al.


PubMed | University Hospital Pedro Ernesto, Centro Universitario Estadual da Zona Oeste and Laboratory of Nanoradiopharmaceuticals
Type: | Journal: BioMed research international | Year: 2015

The off-label use of bevacizumab labeled with 99mTc as a new radiopharmaceutical for imaging of endometriosis is a promising noninvasive, new clinical procedure. The bevacizumab in monoclonal antibodies targeted at vascular endothelial growth factor (VEGF) is superexpressed in cases of endometriosis. In this study we evaluate the imaging of endometriosis lesion in rats (induced to endometriosis) using bevacizumab-99mTc. The results showed that bevacizumab-99mTc imaged the lesion and support his use for Nuclear Medicine applied to gynecology. Also the results appointed that this radiopharmaceutical has a hepatobiliary excretion. It is important to notice that the dose used was almost 0,01% of the usual dose for the bevacizumab.


Do Carmo F.S.,Laboratory of Nanoradiopharmaceuticals | De Souza Albernaz M.,Laboratory of Nanoradiopharmaceuticals | Santos-Oliveira R.,Laboratory of Nanoradiopharmaceuticals
Journal of Analytical Oncology | Year: 2014

The use of somatostatin analogues is growing each year, especially for tumor imaging and treatment. In this scenario the numbers of radionuclides and the perspective of new one are quite promising. In this review we approach the possibilities and give an overview of the trends and possibilities in this area. © 2014 Lifescience Global.


PubMed | Laboratory of Nanoradiopharmaceuticals
Type: | Journal: Anti-cancer agents in medicinal chemistry | Year: 2015

The use of nanobiomaterials is increasing each day. Among the immense variety of nanomaterials developed and studied the hydroxyapatite is one of the most. In this study we developed and tested nano-hydroxyapatite dopped with Ho-166 for bone cancer. The results showed that the nano-hydroxyapatite dopped with Ho-166 has affinity for the bone, as also, the pre-clinical studies support the use as a nano-radiopharmaceuticals for bone cancer treatment and diagnosis.


PubMed | Laboratory of Nanoradiopharmaceuticals
Type: Journal Article | Journal: Current cancer drug targets | Year: 2015

Drug delivery systems are under intense investigation all around the world, especially in oncology research. Indeed, in some cases, like bone metastasis, nanodrugs may represent the last and best choice for both treatment and imaging of early cancer foci. Nuclear medicine has been using MDP labelled with 99mTc as radiopharmaceuticals for many years; however, their use as nanoradiopharmaceuticals is very innovative and creates a new way to establish radiopharmacy in this new scenario offered by nanotechnology. In this study we developed and tested nano-MDP-labelled with 99mTc in rats induced with bone cancer metastasis and the results showed that it may work in patients. However, some further experiments are required in order to initiate protocols in humans.

Loading Laboratory of Nanoradiopharmaceuticals collaborators
Loading Laboratory of Nanoradiopharmaceuticals collaborators